Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807680 | 0.90 | KMT2A (0.64) | KMT2ACNR1MEN1ITGB3ITGAV | |
| SCHEMBL6496672 | 0.88 | KMT2A (0.52) | KMT2AFPR2MEN1ITGB3ITGAV | |
| SCHEMBL6498315 | 0.88 | KMT2A (0.52) | KMT2AFPR2CNR1MEN1ITGB3 | |
| SCHEMBL6498395 | 0.84 | CNR1 (0.54) | KMT2ACNR1MEN1KDM4EALDH1A1 | |
| SCHEMBL27493374 | 0.79 | MAOA (0.57) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL6497268 | 0.77 | ITGB3 (0.53) | KMT2AMEN1ITGB3ITGAVKDM4E | |
| SCHEMBL6505482 | 0.74 | TRPV1 (0.56) | CNR1KDM4ETRPV1ALDH1A1LMNA | |
| SCHEMBL25303812 | 0.73 | CNR1 (0.66) | KMT2AFPR2CNR1KDM4EPLAAT3 | |
| SCHEMBL5394390 | 0.73 | TRPV1 (0.57) | FPR2CNR1TRPV1 | |
| SCHEMBL250873 | 0.72 | PLAAT3 (0.58) | KMT2AFPR2CNR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| CN-1070480-C | 2-amino-benzoxanones for the treatment of viral infections | SEARLE & CO (US) | 2001-09-05 | — | — | CN | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | KMT2A 1555/4885FPR2 1584/4885CNR1 514/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | KMT2A 1859/4885FPR2 1508/4885CNR1 592/4885 |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | KMT2A 4477/4885FPR2 106/4885CNR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.